Compare SPDR Gold Trust (GLD) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? SPDR Gold Trust trades at $383.66 (market cap $139.66B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: SPDR Gold Trust is far larger — about 2.4× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while SPDR Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 74 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| GLD | TAK | |
|---|---|---|
Market Cap | $139.66B | $58.74B |
Volume | 9,544,773 | 3,110,994 |
52-Week High | $495.90 | $19.05 |
52-Week Low | $362.32 | $13.23 |
Typical Hold Time | 74 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD is trading at $375.88, down 1.66% over the past 24 hours amid broader market pressure from rising Treasury yields and Federal Reserve policy uncertainty. The technical picture remains bearish with moving averages and oscillators signaling continued downward momentum, while key support levels cluster around $372-375. Recent news highlights gold's struggle to maintain gains despite weak economic data, with prices testing critical support zones.
The outlook for GLD remains challenged by persistent headwinds from elevated yields and dollar strength, though some analysts see tactical buying opportunities at current levels. Key risks include further Fed tightening and deteriorating technical momentum, while potential catalysts include sustained inflation concerns and geopolitical tensions that could revive safe-haven demand.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
